enGene Therapeutics (ENGN) Total Debt (2022 - 2026)

enGene Therapeutics (ENGN) has 5 years of Total Debt data on file, last reported at $25.4 million in Q3 2026.

• For the quarter ending Q3 2026, Total Debt rose 9.67% year-over-year to $25.4 million; the trailing twelve-month figure through Jul 2026 stood at $25.4 million (up 9.67% YoY), and the FY2025 full-year result was $23.3 million, up 0.66% from the prior year.
• Total Debt was $25.4 million for Q3 2026 at enGene Therapeutics, up from $25.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $40.0 million in Q3 2023 to a low of $9.8 million in Q4 2023.
• A 5-year average of $22.9 million and a median of $23.2 million in 2024 frame the typical range for Total Debt.
• The largest YoY upside for Total Debt was 136.98% in 2024 against a maximum downside of 42.6% in 2024.
• enGene Therapeutics' Total Debt stood at $10.9 million in 2022, then dropped by 10.41% to $9.8 million in 2023, then surged by 136.98% to $23.2 million in 2024, then rose by 0.66% to $23.3 million in 2025, then grew by 8.69% to $25.4 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $25.4 million in Q3 2026, $25.1 million in Q2 2026, and $24.9 million in Q1 2026.